{
    "clinical_study": {
        "@rank": "63680", 
        "acronym": "AFINIVEST", 
        "brief_summary": {
            "textblock": "A study to determine the efficacy of Everolimus(Afinitor\u00ae) as third line therapy in patients\n      with transitional cell carcinoma of the urothelium which failed or progressed after two\n      lines of chemotherapy"
        }, 
        "brief_title": "The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium", 
        "condition": "Urothelial Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Transitional Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of written  informed consent\n\n          -  Male or female aged more than 18 years\n\n          -  Histologically proven transitional cell carcinoma of the urothelium\n\n          -  Metastatic or locally advanced disease not amenable to curative surgery and/or\n             radiotherapy\n\n          -  Recurrence or progression after at least one  chemotherapy regimen  and for\n             unresectable/advanced disease\n\n          -  No more than 2 lines of previous chemotherapy..\n\n          -  Measurable disease (RECIST criteria)\n\n          -  Previously irradiated lesions are not considered measurable- ECOG performance status\n             of 0, 1 or 2\n\n        Exclusion Criteria:\n\n          -  No prior treatment with anti cancer agents, including radiotherapy,  in the last 4\n             weeks.\n\n          -  No currently active CNS involvement\n\n          -  No pregnancy. Women  of child bearing potential must have a negative pregnancy test.\n\n          -  No uncontrolled diabetes\n\n          -  No symptomatic coronary artery disease, myocardial infarction within the last six\n             months, congestive cardiac failure greater than New York Heart Association (NYHA)\n             class II, uncontrolled or symptomatic cardiac arrhythmia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801137", 
            "org_study_id": "2010/23"
        }, 
        "intervention": {
            "intervention_name": "Everolimus (Afinitor\u00ae)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "lastchanged_date": "February 26, 2013", 
        "location": {
            "contact": {
                "email": "c.theodore@hopital-foch.org", 
                "last_name": "Christine Theodore, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Suresnes", 
                    "country": "France", 
                    "state": "Ile de France", 
                    "zip": "92150"
                }, 
                "name": "H\u00f4pital FOCH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicentre Phase III Trial to Determine the Efficacy of RAD 001 (Everolimus, Afinitor) as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium Which Failed or Progressed After First Line Chemotherapy", 
        "overall_contact": {
            "email": "c.theodore@hopital-foch.org", 
            "last_name": "Christine Theodore, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "If a patient has not had an event, Progression-free survival is censored at the date of last adequate tumor assessment.", 
            "measure": "Progression-free survival rate at 12 weeks", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hopital Foch", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hopital Foch", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}